IL3 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, Bellavia et al. genetically fused interleukin-3 (IL-3) to the N-terminal of LAMP-2B to improve the targeting potential of exosomes for the treatment of chronic myeloid leukemia (CML).